Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI's Humira biosimilar
Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent
The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals